Fairvalue-Calculator Fairvalue-Calculator
EN DE

Anxo Pharmaceutical Co (6677) Fair Value & Analysis

Healthcare · TW · Market cap 957M TWD

Price16.80 TWD
Fair Value11.87 TWD
Upside-29.3%
Quality87/100
Evidence: Medium Range 8.86 TWD – 17.72 TWD

Fair value as of: Jun 24, 2026

Analysis

Anxo Pharmaceutical Co (6677) currently trades at 16.80 TWD, while our model-based Fair Value estimate is 11.87 TWD — implying the stock looks roughly 29.3% overvalued today. We read business quality at 87/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

Anxo Pharmaceutical Co., Ltd., a specialty pharmaceutical company, develops, manufactures, and sells pharmaceutical products for medical professionals and patients in Taiwan and internationally. The company offers prescription and over the counter drugs in various therapeutic areas, such as cardiovascular, metabolism, CNS, diabetic, respiratory, anti-infection, dermatology, nephrology, urology, orthopedics, etc. It also offers drugs for antidiabetic/dyslipidaemic agents, cardiovascular/circulatory system, nervous system, hepatology/gastroenterology, anti-infectives/anti-viruses, hemodialysis/urinary system, respiratory system/antihistamine, analgesics, and others; and injections. The company was founded in 2003 and is headquartered in Taipei, Taiwan.

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +1949% Jiangsu Hengrui Pharmaceuticals Co (600276) -46% Sun Pharmaceutical Industries Limited (SUNPHARMA) -44% Zoetis Inc (Z1TS34) -74% Hansoh Pharmaceutical Group (3692) -47% Divi's Laboratories Limited (DIVISLAB) -70%

Frequently asked questions

Is Anxo Pharmaceutical Co (6677) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 11.87 TWD versus a price of 16.80 TWD — about −29% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 6677?
Our 21-model fair value for Anxo Pharmaceutical Co is 11.87 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 16.80 TWD.
What is the quality score of 6677?
Anxo Pharmaceutical Co has a Quality Score of 87/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.